43
BERK-PLANKEN, I.I.L.; HOOGERBRUGGE, N.; STOLK, R.; BOOTSMA, A.H;
Atorvastatin Dose-Dependently decreases hepatic lipase activity in type 2 diabetes.
Diabetes Care, v. 26, p. 427-432, 2003.
BERTOLAMI, M.C. A conexão entre as lipoproteínas e a aterosclerose. Rev Soc
Cariol Estado de São Paulo, São Paulo, v. 10, 2000.
BOEKHOLDT, S.M.; SACKS, F.M.; JUKEMA, J.W.; SHEPHERD, J.; FREEMAN,
D.J.; MACMAHON, A.D.; CAMBIEN, F.; DE GROOTH, G.J.; TALMUD, P.J.;
HUMPHRIES, S.E.; MILLER, G.J.; FIRIKSDOTTIR, G.; GUDNASON, V.; KAUMA,
H.; KAKKO, S.; SAVOLAINEN, M.J.; ARCA, M.; MONTALI, A.; LIU, S.; LANZ, H.J.;
ZWINDERMAN, A.H.; KUIVENHOVEN, J.Á.; KASTELEIN, J.J. Cholesteryl ester
transfer protein TaqIB variant, high-density lipoprotein cholesterol levels,
cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-
analysis of 13,677 subjects. Circulation, v. 111, p. 278-287, 2005.
BRESLOW, J.L. Genetics of Lipoprotein Abnormalities Associated with Coronary
Heart Disease Susceptibility. Annu Rev Genet, v. 34, p. 233- 254, 2000.
BROUSSEAU, M.E.; O’CONNOR, J.J.; ORDOVAS, J.M.; COLLINS, D.; OTVOS,
J.D.; MASSOV, T.; MCNAMARA, J.R.; HANNA, B.R.; ROBINS, S.L.; SCHAEFER,
E.J. Cholesteryl ester transfer protein TaqI B2B2 genotypes is associated with higher
HDL cholesterol levels and lower risk of coronary heart disease end points in men
with HDL deficiency. Arterioscler Thromb Vasc Biol., v. 22, p. 1148-1154, 2002.
CARLQUIST, J.F.; MUHLESTEIN, J.; HORNE, B.; HART, N.; BAIR, T.L.;
MOLHUIZEN, H.O.F.; Anderson, J.L.; The cholesteryl ester transfer protein TaqIB
gene polymorphis predicts clinical benefit of statin therapy in patients with significant
coronary artery disease. Am Heart J, v. 146, p. 1007-1014, 2003.
CARR, M.C.; BRUNZELL, J.D.; DEBB, S.S. Ethnic differences in hepatic lipase and
HDL in Japaneses, blacks, and white Americans: role of central obesity and LIPC
polymorphism. J Lipid Res, v. 45, n. 3, p. 466-473, 2004.
CASAS, J.P.; COOPER, J.; George, J.M. Investigating the genetic determinants of
cardiovascular disease using candidate genes and Meta-analysis of association
studies. Ann Human Genet, v. 70, p. 145-169, 2006.
CHAN, D.C.. WATTS, G.F. Apolipoproteins as markes and managers of coronary
risk. Q J Med, v. 99, n. 5, p. 277-287, 2006.
CHASMAN, D.I.; POSADA, D.; SUBRAHMANYAN, L.; COOK, N.R.; STANTON,
V.P.; RIDKER, P.M. Pharmacogenetic study of statin therapy and cholesterol
reduction. JAMA, v. 16; 291, n. 23, p. 2821-2827, 2004.
CHEN, W.; SRINIVASAN, S.R.; BOERWINKLE, E.; BERENSON, G.S. Hepatic lipase
promoter C-514T polymorphism influences serial changes in HDL cholesterol levels
since childhood: the Bogalusa Heart Study. Atherosclerosis, v. 19, p. 175-182, 2003.